Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276393 · ClinicalTrials.gov registry record · Phase 4
Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT00276393: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT00276393 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00276393, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
Patients with type 1 diabetes trained in multiple daily insulin injection were treated with two diffferent kinds of long acting insulin preparations. The two insulin preparations were glargine and ultralente insulin. Patients were randomized to receive one of the two insulin preparations for the first 4 months followed by the second preparation for a further four months. Short acting insulin used was the same during both periods. We found that glargine insulin was better than ultralente insulin in our study.
Interventions
- DRUG Basal insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2002-07 |
| Est. Completion | 2003-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00276393
The ClinicalTrials.gov registry entry for NCT00276393 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Basal insulin is the first listed.
NCT00276393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00276393 about?
NCT00276393 is a clinical study titled "Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes". Patients with type 1 diabetes trained in multiple daily insulin injection were treated with two diffferent kinds of long acting insulin preparations. The two insulin preparations were glargine and ultralente insulin. Patients were randomized to receive one of the two insulin preparations for the fir...
What is the current status of trial NCT00276393?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2002-07. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00276393?
The interventions under investigation include: Basal insulin (DRUG).
Who is sponsoring clinical trial NCT00276393?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.